We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PM20D1 is a circulating biomarker closely associated with obesity, insulin resistance and metabolic syndrome.
- Authors
Ranyao Yang; Yue Hu; Chi Ho Lee; Yan Liu; Diaz-Canestro, Candela; Ho Yi Fong, Carol; Huige Lin; Cheng, Kenneth K. Y.; Padmanabhan Pravelil, Aparna; Erfei Song; Lam, Karen S. L.; Aimin Xu
- Abstract
Objective: Peptidase M20 domain containing 1 (PM20D1), a secreted enzyme catalysing condensation of fatty acids and amino acids into the bioactive lipids N-acyl amino acids (N AAA), induces uncoupling protein 1 (UCP1)-independent adaptive thermogenesis in brown/beige adipocytes in mice. This study aimed to explore the associations of the circulating levels of PM20D1 and major NAAA with obesity-relate d metabolic complications in humans. Design and methods: Serum concentrations of PM20D1 and NAAA (C18:1-Leu and C18:1-P he) in 256 Chinese subjects, including 78 lean and 178 overweight/obese individuals with or without diabetes, were measured with immunoassays and liquid chromatography–mass spectrometry, respectively. The impact of sulfonylurea and rosiglitazone on their circulating levels was examined in 62 patients with type 2 diabetes. Results: Serum PM20D1 level was significantly elevated in overweight/obese individuals and was closely associated with circulating levels of C18:1-Leu and C18:1-Phe. Furthermore, serum PM20D1, C18:1-Leu and C18:1-Phe concentrations correlated positively with several parameters of adiposity as w ell as fasting and 2 h postprandial glucose, HbA1c, fasting insulin and HOMA-IR independent of BMI and age. Moreover, a significant elevation in PM20D1, C18:1-Leu and C18:1-Phe concentrations corresponding with increases in the number of components of the metabolic syndrome (MetS) was observed. Treatment with sulfonylurea significantly decreased circulating PM20D1, C18:1-Leu and C18:1-Phe in patients with type 2 diabetes. Conclusions: Increased serum levels of PM20D1 and its catalytic products NAA A are closely associated with obesity-related glucose dysregulation, insulin resistance and MetS and can be potentially used as clinical biomarkers for diagnosing and monitoring these disorders.
- Subjects
METABOLIC syndrome; TYPE 2 diabetes; LIQUID chromatography-mass spectrometry; OBESITY; UNCOUPLING proteins; AMINO acids; LEPTIN
- Publication
European Journal of Endocrinology, 2022, Vol 186, Issue 2, p151
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-21-0847